Effect of Anticoagulation Therapy on Clinical Outcomes in Moderate to Severe Coronavirus Disease 2019 (COVID-19)
Overview
- Phase
- Phase 2
- Intervention
- Rivaroxaban
- Conditions
- COVID-19
- Sponsor
- Charite University, Berlin, Germany
- Enrollment
- 111
- Locations
- 24
- Primary Endpoint
- Seven-category ordinal scale recommended by the WHO
- Status
- Terminated
- Last Updated
- 4 years ago
Overview
Brief Summary
Patients with moderate to severe COVID-19 present a very high risk of thromboembolic disease.This multicenter, prospective, randomized, event-driven study evaluates rivaroxaban compared with standard of care with low-molecular-weight heparin (LMWH) or unfractionated heparin (UFH) at prophylactic doses comparing D-dimer levels and the seven-category ordinal scale recommended by the WHO 7 days post randomization in patients with moderate to severe COVID-19.
Experimental intervention/Index test:
Patients randomized into the rivaroxaban arm will receive rivaroxaban 20 mg once daily (OD) until day 7 post randomization or hospital discharge, whichever occurs later, followed by a 28-day-phase of prophylactic anticoagulation with rivaroxaban 10mg OD. Subjects with an eGFR between 30 and 50ml/min/1,73m2, will receive 15mg instead of 20mg OD.
Control intervention/Reference test:
The control group will receive standard of care including LMWH or UFH as thromboprophylaxis.
Duration of intervention per patient:
The total duration of the study treatment is flexible. For out-patients 7 days of therapeutic anticoagulation will be accompanied by 28 days-phase of prophylactic anticoagulation, summing up to 35 days. For subjects that require hospitalization, the duration of therapeutic anticoagulation will be at least 7 days or prolonged until discharge if hospitalized for more than 7 days post randomization.
After discharge from the hospital the subject receives 28 days of thromboprophylaxis with rivaroxaban. No study medication will be given past day 60 post randomization. This adds up to a study duration between 35 and 60 days depending on the duration of the hospital stay.
Follow-up per patient:
The study has a follow-up of 60 days.
Experimental and/or control off label or on label in Germany:
Rivaroxaban has been approved for multiple indications worldwide. Over 100,000 subjects have been studied from Phase 1 through multiple large Phase 4 studies in multiple settings, e.g. for the reduction in the risk of stroke and systemic embolism in arterial fibrillation, deep vein thrombosis and pulmonary embolism, major cardiovascular events. The drug had not been studied in patients with COVID-19 as an anticoagulant agent, yet.
Investigators
Ulf Landmesser
Prof. Dr.
Charite University, Berlin, Germany
Eligibility Criteria
Inclusion Criteria
- •Subject must be willing, understanding and able to provide written informed consent
- •Subject must be a man or a woman with age \> 18 years at screening
- •Subject must have an active moderate to severe COVID-19 confirmed by
- •o A positive SARS-CoV-2 PCR test in the last 14 days
- •At least one of the following features should be present
- •D-Dimer elevation \> 1.5 ULN (age adjusted cut-offs) AND/OR
- •Cardiac injury reflected by an elevation in hs-cTnT \> 2.0 upper limit of normal (ULN) AND at least one of the following conditions:
- •Known coronary artery disease (CAD)
- •Known diabetes mellitus
- •Active smoking
Exclusion Criteria
- •Subject has a very high bleeding risk: Any condition that, in the opinion of the investigator, contraindicates anticoagulant therapy or would have an unacceptable risk of bleeding, such as, but not limited to, the following:
- •Any bleeding (defined as bleeding requiring hospitalization, transfusion, surgical intervention, invasive procedures, occurring in a critical anatomical site, or causing disability) within 1 months prior to randomization or occurring during index hospitalization.
- •Major surgery, biopsy of a parenchymal organ, ophthalmic surgery (excluding cataract surgery), or serious trauma (including head trauma) within 4 weeks before randomization.
- •A history of hemorrhagic stroke or any intracranial bleeding at any time in the past, evidence of primary intracranial hemorrhage on CT or magnetic resonance imaging scan of the brain, or clinical presentation consistent with intracranial hemorrhage. This applies as well to subjects hospitalized for ischemic stroke upon randomization.
- •Subject has a history of or current intracranial neoplasm (benign or malignant), cerebral metastases, arteriovenous (AV) malformation, or aneurysm.
- •Active gastroduodenal ulcer, defined as diagnosed within 1 months or currently symptomatic or known AV malformations of the gastrointestinal tract.
- •Platelet count \<90,000/μl at screening.
- •Patients with the diagnosis of bronchiectasis, that due to the investigator judgement are at an increased bleeding risk.
- •Subject has any of the following diseases in the medical history:
- •Active cancer (excluding non-melanoma skin cancer) defined as cancer not in remission or requiring active chemotherapy or adjunctive therapies such as immunotherapy or radiotherapy. Chronic hormonal therapy (e.g. tamoxifen, anastrozole, leuprolide acetate) for cancer in remission is allowed.
Arms & Interventions
Rivaroxaban
Subjects will receive treatment with rivaroxaban. (for more information see intervention description)
Intervention: Rivaroxaban
Standard of Care
Subjects will receive standard of care (SOC) treatment SOC with prophylactic LMWH or UFH
Intervention: Standard Of Care (SOC)
Outcomes
Primary Outcomes
Seven-category ordinal scale recommended by the WHO
Time Frame: 7 days post randomization
D-dimer level
Time Frame: 7 days post randomization
Secondary Outcomes
- Composite endpoint of venous thromboembolism (DVT and/or fatal or non-fatal PE), arterial thromboembolism, new myocardial infarction, non-hemorrhagic stroke, all-cause death or progression to intubation and invasive ventilation(35 days post randomization)